Differential effects of olaparib on neutrophils vs. mononuclear cells have also recently been noted in a model of colitis: in this model, neutrophilia was not affected by the PARP inhibitor, while the changes in lymphocyte and monocyte numbers were partially normalized by the PARP inhibitor [43]. Here, PARP1 is linked to colitis.